Several studies documented the key role of oxidative stress and abnormal production of reactive oxygen species (ROS) in the pathophysiology of muscular dystrophies (MDs). The sources of ROS, however, are still controversial as well as their major molecular targets. This study investigated whether ROS produced in mitochondria by monoamine oxidase (MAO) contributes to MD pathogenesis. Pargyline, a MAO inhibitor, reduced ROS accumulation along with a beneficial effect on the dystrophic phenotype of Col6a1 -/mice, a model of Bethlem myopathy and Ullrich congenital MD, and mdx mice, a model of Duchenne MD. Based on our previous observations on oxidative damage of myofibrillar proteins in heart failure, we hypothesized that MAO-dependent ROS might impair contractile function in dystrophic muscles. Indeed, oxidation of myofibrillar proteins, as probed by formation of disulphide cross-bridges in tropomyosin, was detected in both Col6a1 -/and mdx muscles. Notably, pargyline significantly reduced myofiber apoptosis and ameliorated muscle strength in Col6a1 -/mice. This study demonstrates a novel and determinant role of MAO in MDs, adding evidence of the pivotal role of mitochondria and suggesting a therapeutic potential for MAO inhibition.
Introduction
Muscle dystrophies (MDs) are a heterogeneous group of inherited human disorders primarily affecting skeletal muscles. Typically, MDs show diffuse wasting and weakness of muscles, associated with degeneration and regeneration of muscle fibers. Duchenne muscular dystrophy is the most common and severe form of MD worldwide. This progressive and lethal X-linked myopathy is characterized by deficiency of dystrophin, a subsarcolemmal protein critical in membrane stabilization and prevention of contraction-induced cell membrane damage (1) .
Although mutations in components of the dystrophin glycoprotein complex are responsible for the most devastating MDs, mutations of genes coding for extracellular matrix proteins play a causative role in other forms of MDs. Indeed, another group of MDs is due to inherited mutations in genes encoding collagen VI. Collagen VI is a major component of the endomysium, where it is localized just outside the basement membrane of muscle fibers. Mutations of Collagen VI cause two muscle diseases in humans, namely Bethlem myopathy (MIM#158810) and Ullrich congenital muscular dystrophy (MIM#254090) (2) . Bethlem myopathy is a relatively mild and slowly progressive myopathic disorder, whereas UCMD is a severe and rapidly progressive muscle disease usually causing early death due to respiratory failure.
Several studies documented the key role of oxidative stress and abnormal production of ROS in the pathophysiology of MDs (3) (4) (5) (6) . Antioxidant treatments have been shown to counteract myocyte injury in mdx mice demonstrating the key role of reactive oxygen species (ROS) in MD pathogenesis (7) .
Indeed, ROS formation appears a causative event rather than a consequence of muscle degeneration (8) . Mitochondria are generally indicated as a major source of ROS. In fact, recent studies provided clear evidence of the crucial role of mitochondria in MDs. This concept is supported by genetic or pharmacological reduction of the open probability of the mitochondrial permeability transition pore, that has been demonstrated to prevent myofiber injury characterizing experimental models of MDs (9) (10) (11) .
Besides the respiratory chain, a relevant source of ROS in mitochondria is represented by monoamine oxidases (MAO). These flavoproteins, which exist in two isoforms, MAO-A and MAO-B, are located in the outer mitochondrial membrane and catalyze the oxidative deamination of neurotransmitters and dietary amines, generating hydrogen peroxide (12) . The monoamine catabolism generates aldehydes, ammonia and hydrogen peroxide. MAO has been extensively studied at the level of the central nervous system while their role in other tissues has been scarcely investigated. Nevertheless, evidence has been provided that MAO contributes to cardiac diseases (13, 14) . As far as the targets of ROS are concerned, we hypothesized the myofibrillar proteins could represent important intracellular targets of ROS involved in contractile dysfunction of the dystrophic muscle. Indeed, in several models of myocardial dysfunction, such as coronary microembolization and heart failure, we demonstrated that myofibrillar proteins, such as tropomyosin (Tm), actin and desmin were modified by ROS and that the contractile impairment was related to formation of disulphide cross-bridges in Tm (15, 16) .
In the present study we investigated the role of MAO in skeletal muscles of two murine models for different forms of MDs, namely Col6a1 -/and mdx mice. Our findings demonstrate that accumulation of ROS related to MAO activity plays a pivotal role in both loss of cell viability and contractile derangements of dystrophic skeletal muscles. This is supported by the protective efficacy of the MAO inhibitor pargyline on oxidative stress, alterations of muscle structure and function, and loss of cell viability in the two murine MD models.
Results

Myofibrillar protein oxidation in Col6a1 -/mice and effects of MAO inhibition
Two murine models of MD were considered in this study: Col6a1 -/mice, which lack collagen VI due to null mutation of the gene coding for the α1(VI) subunit (2), and mdx mice which lack dystrophin (17) . We first investigated the activity of MAO in skeletal muscle and found that it was significantly increased in six-month-old Col6a1 -/mice as compared to wild-type littermates ( Figure 1A ). The increased MAO activity was associated with an increase of MAO-A protein levels in Col6a1 -/muscle ( Figure 1B ). To assess the role of MAO-dependent ROS accumulation, Col6a1 -/mice were randomized into groups receiving i.p. treatment with pargyline (50 mg/kg/d), a MAO-A and MAO-B inhibitor, or vehicle for one week. MAO activity was abolished after the treatment ( Figure 1A ).
Next, we quantified ROS production in six-month-old Col6a1 -/mice. When compared to age-matched wild-type mice, muscles of Col6a1 -/mice showed an increased accumulation of ROS, as revealed by increased dihydroethidium (DHE) fluorescence in diaphragm and gastrocnemius ( Fig 1C) . Importantly, the abnormal production of ROS in Col6a1 -/muscles was significantly decreased upon pargyline treatment ( Figure 1C and D).
Then, we investigated whether MAO-dependent ROS accumulation caused oxidative modifications of myofibrillar proteins, as probed by Tm oxidation. Indeed, we previously demonstrated that, among myofibrillar proteins, Tm is particularly susceptible to oxidative stress (16) . Immunoblots with anti-Tm displayed additional high molecular mass bands in Col6a1 -/diaphragm, which is the most affected muscle in this murine model ( Figure 2A ). The appearance of these bands, which were much fainter in samples obtained from wild-type littermates, reflected disulfide cross-bridges (DCB) formation because they were visible only under non-reducing electrophoresis. The band at 82 kDa was attributed to a dimer of Tm, while the bands with an apparent molecular mass > 220 kDa could reflect high molecular mass complexes among several monomers of Tm, or between Tm and other proteins. It is worth pointing out that skeletal Tm contains the αas well as the β-isoform. At variance from the presence of a single cysteine in the α-isoform, β-Tm contains two Cys residues that might result in the covalent aggregation of more than two proteins by means of DCB formation. Indeed mass spectrometric analysis performed on the high molecular mass Tm complexes identified the myosin heavy chain ( Supplemental Table) . DCB content was 3.2±0.4 fold higher in Col6a1 -/as compared to wild-type muscles and was significantly reduced by pargyline treatment ( Figure 2B ).
MAO inhibition ameliorates muscle apoptotic phenotype of Col6a1 -/mice
Contractile impairment and high apoptosis rate are two specific features of skeletal muscles of Col6a1 -/mice (11) . We therefore investigated whether pargyline treatment was able to improve cell survival and to counteract the apoptotic phenotype observed in Col6a1 -/mice. Occurrence of apoptosis was evaluated by the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL).
The number of TUNEL-positive nuclei was higher in Col6a1 -/mice as compared to wild-type littermates (62.4±2.3 versus 2.7±1.2 nuclei/mm 2 ), and pargyline treatment reduced the occurrence of TUNEL-positive nuclei to a level (6.9±1) that was not significantly different from that observed in wild-type mice ( Figure 3A ). Direct evidence of a protective effect of MAO inhibition on muscle damage was provided by immunohistochemical staining of skeletal muscle with IgG antibody. In fact, the circulating IgG can enter into the myfibers of dystrophic mice due to altered sarcolemma integrity, thus allowing their detection by FITC-conjugated anti-mouse IgG (18, 19) . Damaged fibers, positive to the immunohistochemical staining for IgG, were present in Col6a1 -/diaphragm and their number was significantly decreased by pargyline treatment ( Figure 3B ). Additional evidence of muscle damage and protection by MAO inhibition was provided by vital staining with Evans blue. Supporting the finding obtained by permeability to IgG, several damaged myofibers stained by Evans blue were found in Col6a1 -/but not in wild-type diaphragm, and this alteration was largely reduced in the diaphragm of Col6a1 -/mice treated with pargyline ( Figure 3C ). Morphometric analysis of myofiber cross-sectional areas in tibialis anterior and diaphragm showed that Col6a1 -/muscles contained myofibers of different sizes, with a prevalence of small fibers. This pathological sign was markedly reduced in pargylinetreated Col6a1 -/muscles, which showed more uniform fiber size, similarly to wild-type mice ( Figure   3D and E).
MAO inhibition ameliorates muscle dysfunction in Col6a1 -/mice.
Biochemical and histological analyses were paralleled by functional assessment of the contractile performance of muscles in vivo and isolated muscle fibers in vitro. Single skinned muscle fibers dissected from gastrocnemius muscle were maximally calcium-activated at optimal sarcomere length.
Col6a1 -/fibers developed lower isometric tension than wild-type fibers, as previously reported (11, 20) .
The contractile impairment disappeared in the fibers of pargyline-treated Col6a1 -/mice ( Figure 4A ). This in vitro evidence was further supported by in vivo findings, as pargyline treatment significantly increased the normalized force of gastrocnemius muscle of Col6a1 -/mice ( Figure 4B ). We finally tested whether treatment with pargyline could improve the voluntary exercise performance of Col6a1 -/mice, tested by means of running-wheel. After acclimatizing mice for one week to a wheel placed in their cage, we measured the daily average distance. The pargyline-treated Col6a1 -/mice showed a significant improvement in the exercise performance compared to untreated mice ( Figure 4C ).
MAO inhibition rescues dystrophic phenotype in mdx mice
The findings obtained in Col6a1 -/mice prompted us to investigate whether ROS generated by MAO might play a role also in mdx mice, where ROS accumulation has been previously demonstrated (5, 8) Interestingly, MAO activity increased in gastrocnemius muscle of mdx mice along with an increase in MAO-A protein levels (Supplemental Figure) , in accordance to what observed in Col6a1 -/mice.
Gastrocnemius and quadriceps of five-week-old mdx mice displayed a significant increase in both ROS formation and Tm oxidation ( Table 1 and Figure 5A ). In fact, DCB increased by 2.84±0.31 and 2.34±0.28 folds in gastrocnemius and quadriceps muscle, respectively. Importantly, these oxidative modifications were significantly decreased after i.p. treatment with pargyline for one week ( Figure 5B ).
Morphometric analysis of myofiber cross-sectional areas in gastrocnemius muscle confirmed that mdx contained myofibers of different sizes, with a significant incidence of small fibers, while pargyline normalized the fiber area distribution ( Figure 6A and B). In addition, pargyline was able to reduce tissue inflammation occurring in mdx skeletal muscles ( Figure 6A ). The occurrence of apoptosis was markedly increased in mdx mice, yet pargyline treatment led to a significantly lower incidence in the number of TUNEL-positive nuclei of mdx mice ( Figure 6C ). Taken together, these results indicate that also in mdx mice ROS generated by MAO are relevant to the dystrophic mechanism and that MAO inhibition protects dystrophic skeletal muscle by reducing myofiber degeneration and ROS production.
Discussion
The present study demonstrates that MAO is a major source of ROS in two murine models of MDs and that its inhibition is able to reduce the occurrence of myofibrillar protein oxidation and myofiber defects. In addition, beside reducing biochemical and histological alterations, MAO inhibition ameliorates contractile performance highlighting the relevance of mitochondrial ROS formation in MDs. Indeed the present study lends support to the concept, developed in cardiac studies (14) , that oxidative stress induced by mitochondrial dysfunction causes both loss of vitality and contractile impairment partly related to the oxidation of myofibrillar proteins.
Although the loss of muscle strength in MDs is partly due to myofiber degeneration, the loss of cell viability is not sufficient to explain entirely the impairment in contractile performance of dystrophic muscles. Additional components have to contribute, since tension development is significantly decreased not only in structurally abnormal fibers, but also in fibers without any detectable sign of degeneration, particularly in skeletal muscles of Col6a1 -/mice (11) . Similar observations of force loss in apparently undamaged fibers of dystrophic muscles have been reported also in other animal models (21) . These findings imply that force loss is directly related with an impaired myofibrillar mechanism of force generation. It is likely that downstream the specific primary biochemical defect (the mutation and its direct impact on the protein) several cell processes are affected within muscle fibers. Oxidative stress, minimal mechanical damage and cell death have been proposed as mechanisms causing the loss of contractile force in MDs (2, 3, (5) (6) (7) (8) (9) 22, 23) . Besides contributing to cell death, the accumulation of ROS is likely to alter the mechanical function of myofibers by means of protein modifications.
In this respect we investigated whether myofibrillar proteins can represent intracellular targets of ROS causing the contractile impairment Col6a1 -/mice muscles. The oxidative processes affect most amminoacid residues. Cys and Met residues are particularly sensitive to oxidation by ROS and generate disulfides and sulfoxide, respectively (24) . Indeed, we previously found that contractile proteins, such as actin and Tm, undergo both reversible and irreversible oxidative processes during myocardial ischemia and reperfusion (15) . Moreover, we have recently demonstrated that the extent of protein oxidation correlates with the degree of contractile impairment in pigs subjected to coronary microembolization (16) . The present results show that oxidation at the level of Cys residues also occurred in dystrophic muscles. Tm oxidation was detected as high-molecular-weight bands in western blots performed under non-reducing conditions. Tm oxidation is likely to hamper contractility. This hypothesis is supported by the localization of Cys residues. In fact, Cys190 is located at the interface with troponin T and DCB formation is likely to alter protein interactions that are crucial for contractile activity. This concept is supported by experimental models and clinical findings relating Tm alterations to contractile impairment (25) . Although the amount of oxidized Tm is relatively modest, it has to be pointed out that severe contractile abnormalities have been reported for cardiomyocytes harboring a minor fraction of altered myofibrillar proteins. Indeed, this was the case with the original report of inborn error of Tm (26) . Actually, the determination of the contractile performance in vivo and in vitro gave support to the idea that the impairment is counteracted by pargiline treatment which reduces ROS production and accumulation.
Besides altering myofibrillar proteins, oxidative stress has been associated with an increased occurrence of cell death. While lending support to the concept that mitochondria are the most relevant cellular site for ROS formation, the protective role elicited by MAO inhibition indicates that oxidative stress is causally linked to both contractile dysfunction and cell death characterizing MDs. In addition, MAO-induced ROS formation further supports the crucial contribution of mitochondria to MDs pathophysiology suggested by recent reports (9) (10) (11) . In fact, mitochondria have recently received attention due to the demonstrated role of the permeability transition pore (PTP) in MDs. PTP inhibition was found to limit histological alterations in Col6a1 -/- (11) as well as mdx (9) mice and pilot studies have demonstrated the therapeutic efficacy of PTP inhibitors, namely cyclosporin A and Debio 025 (9, 23, (27) (28) (29) . Furthermore, ablation of cyclophilin D, a mitochondrial protein that increases the PTP open probability, prevents biochemical and structural alterations observed in different MD models (9, 10) . However, at present it is still difficult to link changes occurring at the level of plasma membrane or even outside the cell, such as loss of collagen VI, with mitochondrial dysfunction related to processes occurring within the inner mitochondrial membrane, such as PTP opening. Such a link can be provided by oxidative stress. In fact, changes in the composition of extracellular matrix might be sensed by plasma membrane integrins that have been shown to convey intracellular signals resulting in increased ROS formation (30). Besides NADPH oxidase activation, mitochondria have been indicated as the main site for integrin-dependent ROS formation (31,32), although the signaling pathways and the mitochondrial sites have not been elucidated yet. Mitochondrial ROS generation, that according to our data is mostly catalyzed by MAO, is likely to be linked to PTP through a vicious cycle whereby an increased ROS formation increases PTP open probability, and vice versa (33). In cardiomyocytes, MAO inhibition was found to reduce ROS formation as well as Tm oxidation, prevent PTP opening and decrease cell death induced by post-ischemic reperfusion (34) . In addition, MAO plays a prominent role in cardiomyocyte hypertrophy in vitro and in its progression toward heart failure in vivo (14) .
These concepts are now extended to skeletal muscle. Indeed the present findings point to mitochondria as the major site, and MAO as the major source, of ROS formation. Previous studies demonstrated the efficacy of N-acetylcysteine or polyphenols from green tea extracts in ameliorating the muscle pathophysiology of mdx mice (7, 35) . However, these drugs can only reduce the level of ROS that are already formed, by acting as a scavenger. Pargyline instead acts by preventing ROS formation, thus making this class of inhibitors much more attractive.
In conclusion, this study provides evidence that MAO-dependent ROS accumulation is a major determinant of both oxidative modifications of myofibrillar proteins and cell death resulting in a marked impairment of contractile function. Therefore, MAO inhibition protects dystrophic skeletal MDs by using MAO inhibitors appears extremely interesting, since these compounds are already used in clinical settings for the treatment of various neurological disorders (12) . Therefore these findings provide a solid rationale for exploiting MAO inhibition as a novel therapeutic approach in MDs. In addition, the increased oxidation of Tm in dystrophic muscles (that is reduced upon protective intervention, i.e. MAO inhibition) suggests that oxidative modifications of contractile proteins might be exploited as novel diagnostic tools to evaluate both the severity of the disease and the efficacy of a given treatment.
Materials and Methods
Mice and pargyline treatment in vivo. Col6a1 +/mice were backcrossed in the inbred C57BL/6J strain for eight generations as described (11) , and data were obtained by comparing Col6a1 -/mice with their wild-type littermates. Wild-type C57BL/10 mice and mdx (in the C57BL/10 background) were Dihydroethidium staining for ROS detection. Dihydroethidium (DHE) is oxidized by ROS, forming ethidium bromide, which emits red fluorescence when intercalates with DNA (36) . Skeletal muscle cryosections (10-µm thick) were incubated with 5 µM DHE (Sigma) in PBS at 37°C for 30 min in humid atmosphere and in the dark, washed twice with PBS, mounted and visualized with an Olympus IMT-2 inverted microscope, equipped with a xenon lamp and a 12-bit digital cooled CCD camera (Micromax, Princeton Instruments) as previously described (37) . For detection of the fluorescence, 568±25 nm excitation and 585 nm longpass emission filter settings were used. Data were acquired and analysed using Metamorph software (Universal Imaging).
Protein extraction and immunoelectrophoresis. Protein extracts were prepared as described (16) .
Immunoblotting were stained with the following antibodies: anti-Tm CH1 clone (Sigma), anti-MAO-B
D-16 and anti-MAO-A H-70 clone (Santa Cruz). In anti-Tm immunoblots the high molecular mass
peptides were attributed to disulfide cross-bridge (DCB) formation by comparing electrophoreses carried out in the absence or in the presence of β-mercaptoethanol as described (16) . Quantitation of to identify all nuclei, as described previously (11) . The total number of nuclei and number of TUNELpositive nuclei were determined in randomly selected fibers using a Zeiss Axioplan microscope equipped with a Leica DC 500 camera. Membrane permeability of skeletal muscle was directly visualized by immunohistochemical staining with IgG (18, 19) . Cryosections (10-µm thick) were incubated with anti-mouse fluorescein isothiocyanate-conjugated IgG, washed twice with PBS, mounted and visualized with an Olympus IMT-2 inverted microscope as previously described (37) using excitation/emission cubes of 488/525±25 nm bandpass. Evans blue dye staining of muscles in vivo was performed by i.p. injection with 0.2 ml Evans blue (10 mg/ml in phosphate-buffered saline, Sigma). Mice were sacrificed after 16-18 h and diaphragms were fixed with 4% paraformaldehyde overnight at 4°C. After fixation, the samples were observed by means of light microscopy.
Muscle functional assessment. Single myofibers were isolated from Col6a1 -/gastrocnemius muscle, chemically skinned as described (38) and tension was measured during maximal isometric activation (pCa = 4.5, T = 20°C, initial sarcomere length = 2.75 µm). Force measurements were performed in the left and/or right gastrocnemius muscle of anaesthetized mice by electrical stimulation through the sciatic nerve, as described previously (19) . Voluntary exercise was evaluated by placing a wheel in the cage. Before the treatment, mice were placed in separate cages with wheel to acclimatize, then the average distance covered by each mouse in 24 hours during the treatment was measured using an automatic counter.
Statistics. All data are expressed as the mean ± s.e.m. We analyzed data with the unpaired Student's ttest, and values with P < 0.05 were considered significant.
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